



Calibrated scores Heidelberg vs. New York

Identical classification	96% (51/53)
Discrepant classification	0% (0/53)
No match in one center	4% (2/53)



b

Analyzed in Heidelberg



Analyzed in New York



Amplification EGFR, deletion CDKN2A/B, gain Chr 7, loss Chr 10 in glioblastoma




Loss of Chr 22 with homozygous deletion of SMARCB1 in ATRT



Isochromosome 17q in medulloblastoma

c



d

